World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
83
Citations
25594
World Ranking
1438
National Ranking
732

H. Kim Lyerly publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where H. Kim Lyerly sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 433 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

H. Kim Lyerly D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where H. Kim Lyerly sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 83 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

H. Kim Lyerly is affiliated with Duke University in the United States. Their research spans multiple disciplines primarily within medicine, biochemistry, genetics and molecular biology, and immunology and microbiology. Specific subfields where they have contributed include oncology, immunology, molecular biology, cancer research, and radiology, nuclear medicine, and imaging.

The scientist's work focuses on several interconnected topics in biomedical research. These topics include:

  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cancer Cells and Metastasis
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research

They have published extensively, with frequent contributions to several well-known journals. The primary publication venues include:

  • Cancer Research
  • Cancer Immunology Research
  • Clinical Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)

Frequent collaborators in their research efforts have included Zachary C. Hartman, Michael A. Morse, Erika J. Crosby, Gangjun Lei, and Timothy N. Trotter.

Among notable recent publications authored by or including Lyerly are:

  • Exposure to low-dose ambient fine particulate matter PM2.5 and Alzheimer's disease, non-Alzheimer's dementia, and Parkinson's disease in North Carolina (2021), published in PLoS ONE
  • DC-CIK as a widely applicable cancer immunotherapy (2020), published in Expert Opinion on Biological Therapy
  • Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy (2021), published in Clinical Cancer Research
  • Sperm DNA methylation altered by THC and nicotine: Vulnerability of neurodevelopmental genes with bivalent chromatin (2020), published in Scientific Reports
  • Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio (2020), published in Journal for ImmunoTherapy of Cancer

Best Publications

  • A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

    Michael A Morse;Jennifer Garst;Takuya Osada;Shubi Khan

  • Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1

    SS Hwang;TJ Boyle;HK Lyerly;BR Cullen;BR Cullen

  • ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

    Robert Yarchoan;Kent J. Weinhold;H. Kim Lyerly;Edward Gelmann

  • Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

    S K Nair;D Boczkowski;M Morse;R I Cumming

  • Induction of Tumor Immunity and Cytotoxic T Lymphocyte Responses Using Dendritic Cells Transfected with Messenger RNA Amplified from Tumor Cells

    D Boczkowski;S K Nair;J H Nam;H K Lyerly

  • Migration of Human Dendritic Cells after Injection in Patients with Metastatic Malignancies

    M A Morse;R E Coleman;G Akabani;N Niehaus

  • A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen

    M. A. Morse;Yuping Deng;D. Coleman;S. Hull

  • Immunotherapy of cancer with dendritic-cell-based vaccines

    E Gilboa;S K Nair;H K Lyerly

  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

    Ulrich Keilholz;Jeffrey Weber;James H. Finke;Dmitry I. Gabrilovich

  • Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines

    Michael A. Morse;Amy C. Hobeika;Takuya Osada;Delila Serra

  • Use of Paravertebral Block Anesthesia in the Surgical Management of Breast Cancer: Experience in 156 Cases

    Eamonn Coveney;Christina Weltz;Roy Greengrass;J. Iglehart

  • Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: The challenge ahead

    William H Goodson;Leroy Lowe;David O Carpenter;Michael Gilbertson

  • A review of the health impacts of barium from natural and anthropogenic exposure

    Julia Kravchenko;Thomas H. Darrah;Richard K. Miller;H. Kim Lyerly

  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

    Takuya Osada;Gabriel Chong;Robert Tansik;Timothy Hong

  • Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack

    H K Lyerly;T J Matthews;A J Langlois;D P Bolognesi

  • Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion

    T J Matthews;K J Weinhold;H K Lyerly;A J Langlois

  • Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations

    Takuya Osada;Minyong Chen;Xiao Yi Yang;Ivan Spasojevic

  • The Anti-Helminthic Niclosamide Inhibits Wnt/Frizzled1 Signaling

    Minyong Chen;Jiangbo Wang;Jiuyi Lu;Michael C. Bond

  • Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.

    Smita K. Nair;Michael Morse;David Boczkowski;R. Ian Cumming

  • Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.

    M H Malim;W W Freimuth;J Liu;T J Boyle

  • HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.

    K J Weinhold;H K Lyerly;S D Stanley;A A Austin

  • Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA.

    Smita K. Nair;Shelley Hull;Doris Coleman;Eli Gilboa

  • Investigation of HIFU-induced anti-tumor immunity in a murine tumor model

    Zhenlin Hu;Xiao Yi Yang;Yunbo Liu;Georgy N Sankin

Frequent Co-Authors

Michael A. Morse
Michael A. Morse Duke University
Timothy M. Clay
Timothy M. Clay Duke University
Larry S. Barak
Larry S. Barak Duke University
Donna Niedzwiecki
Donna Niedzwiecki Duke University
Amy P. Abernethy
Amy P. Abernethy Duke University
Kent J. Weinhold
Kent J. Weinhold Duke University
Mary L. Disis
Mary L. Disis University of Washington
Dani P. Bolognesi
Dani P. Bolognesi Duke University
Smita Nair
Smita Nair Duke University
Andrea Amalfitano
Andrea Amalfitano Michigan State University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can broaden career options and enhance expertise in the field. Many students consider accelerated nursing paths, and there are several programs that stand out in terms of accessibility. If you’re looking for options, you might want to review the easiest ABSN programs to get into, which offer a streamlined path to becoming a registered nurse.

Similarly, if your goal is to enter nursing quickly and efficiently, understanding which LPN programs are easiest to get into can provide valuable guidance. Licensed Practical Nurse programs often serve as stepping stones toward advanced nursing degrees and offer hands-on experience that complements immunology studies.

For those aiming to advance into specialized roles, such as Nurse Practitioners, it’s helpful to explore nurse practitioner programs with easy admission. These programs balance flexibility with opportunity, making them attractive for healthcare professionals seeking to expand their scope of practice.

Lastly, mental health is a critical area connected to immunology through the mind-body interface. Online programs like the best PMHNP programs online offer excellent clinical placement rates and prepare graduates for impactful careers as Psychiatric Mental Health Nurse Practitioners, a growing field within healthcare.

Best Scientists Citing H. Kim Lyerly

Trending Scientists